Last reviewed · How we verify
L-Alanyl/L-Glutamine
L-Alanyl/L-Glutamine is a dipeptide that provides essential amino acids to support protein synthesis and cellular metabolism, particularly in critically ill or nutritionally compromised patients.
L-Alanyl/L-Glutamine is a dipeptide that provides essential amino acids to support protein synthesis and cellular metabolism, particularly in critically ill or nutritionally compromised patients. Used for Nutritional support in critically ill patients, Post-operative metabolic support, Patients with impaired gastrointestinal function requiring parenteral or enteral nutrition.
At a glance
| Generic name | L-Alanyl/L-Glutamine |
|---|---|
| Also known as | Evitar |
| Sponsor | University Hospital Muenster |
| Drug class | Amino acid supplement / Nutritional therapeutic |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Nutritional Support |
| Phase | Phase 3 |
Mechanism of action
This dipeptide formulation delivers two conditionally essential amino acids—alanine and glutamine—that play critical roles in protein metabolism, immune function, and gut barrier integrity. Glutamine serves as a primary fuel source for enterocytes and immune cells, while alanine participates in gluconeogenesis and the glucose-alanine cycle. The combination is designed to improve nitrogen balance and reduce muscle catabolism in clinical settings such as critical illness or major surgery.
Approved indications
- Nutritional support in critically ill patients
- Post-operative metabolic support
- Patients with impaired gastrointestinal function requiring parenteral or enteral nutrition
Common side effects
- Hyperglycemia
- Fluid overload
- Electrolyte imbalances
- Infusion site reactions
Key clinical trials
- Citrullinemia for the Prediction of Enteral Nutrition Tolerance Among Critically Ill Patients (NA)
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (PHASE2)
- Perioperative Supplementation With Immunonutrition and Its Impact on Surgical Outcome and Pain in Oral Cavity or Mandibular Tumours (NA)
- Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy (NA)
- Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF (PHASE3)
- Effect of Parenteral Glutamine on Myocardial Injury and Inflammation Biomarkers (NA)
- Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients (NA)
- Preoperative Immunonutrition and Cardiac Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Alanyl/L-Glutamine CI brief — competitive landscape report
- L-Alanyl/L-Glutamine updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI